Kin A - Search Results

1

[Onset of Testicular Plasmacytoma in a Patient with Refractory Multiple Myeloma].

Kin A, Manabe M, Sogabe N, Nanno S, Hatanaka S, Morimoto K, Yoneda Y, Mazaki T, Koh KR. Kin A, et al. Gan To Kagaku Ryoho. 2023 Dec;50(12):1347-1349. Gan To Kagaku Ryoho. 2023. PMID: 38247079 Japanese.

2

Thresholds and alternative states in a Neotropical dry forest in response to fire severity.

Peinetti HR, Bestelmeyer BT, Chirino CC, Vivalda FL, Kin AG. Peinetti HR, et al. Among authors: kin ag. Ecol Appl. 2024 Mar;34(2):e2937. doi: 10.1002/eap.2937. Epub 2023 Dec 22. Ecol Appl. 2024. PMID: 38071696

3

Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission.

Modi D, Alkassis S, Kim S, Kin A, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Modi D, et al. Among authors: kin a. Leuk Lymphoma. 2023 Jul-Aug;64(7):1285-1294. doi: 10.1080/10428194.2023.2206181. Epub 2023 May 8. Leuk Lymphoma. 2023. PMID: 37154379

4

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.

Paul B, Liedtke M, Khouri J, Rifkin R, Gandhi MD, Kin A, Levy MY, Silbermann R, Cottini F, Sborov DW, Sandhu I, Villarreal L, Murphy M, Gu L, Chen A, Rajakumaraswamy N, Usmani SZ. Paul B, et al. Among authors: kin a. Future Oncol. 2023 Jan;19(1):7-17. doi: 10.2217/fon-2022-0975. Epub 2023 Feb 13. Future Oncol. 2023. PMID: 36779512 Free PMC article.

5

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma.

Derman BA, Zonder J, Reece D, Cole C, Berdeja J, Stefka AT, Major A, Kin A, Griffith K, Jasielec J, Jakubowiak AJ. Derman BA, et al. Among authors: kin a. Blood Adv. 2023 Oct 10;7(19):5703-5712. doi: 10.1182/bloodadvances.2022008866. Blood Adv. 2023. PMID: 36763537 Free PMC article. Clinical Trial.

6

Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.

Al-Share B, Assad H, Abrams J, Deol A, Alavi A, Modi D, Kin A, Ratanatharathorn V, Uberti J, Ayash L. Al-Share B, et al. Among authors: kin a. J Oncol. 2022 Sep 30;2022:3472324. doi: 10.1155/2022/3472324. eCollection 2022. J Oncol. 2022. PMID: 36213836 Free PMC article.

7

Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD Jr, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Derman BA, et al. Among authors: kin a. JAMA Oncol. 2022 Sep 1;8(9):1278-1286. doi: 10.1001/jamaoncol.2022.2424. JAMA Oncol. 2022. PMID: 35862034 Free PMC article. Clinical Trial.

8

Organic Cation Transporter I and Na⁺ /taurocholate Co-Transporting Polypeptide are Involved in Retrorsine- and Senecionine-Induced Hepatotoxicity in HepaRG cells.

Enge AM, Kaltner F, Gottschalk C, Kin A, Kirstgen M, Geyer J, These A, Hammer H, Pötz O, Braeuning A, Hessel-Pras S. Enge AM, et al. Among authors: kin a. Mol Nutr Food Res. 2022 Jan;66(2):e2100800. doi: 10.1002/mnfr.202100800. Epub 2021 Dec 11. Mol Nutr Food Res. 2022. PMID: 34826203

9

Improved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.

Shah H, Jang H, Singh P, Kosti J, Kin A, Alavi A, Ratanatharathorn V, Ayash L, Uberti J, Ramchandren R, Kim S, Deol A. Shah H, et al. Among authors: kin a. Leuk Lymphoma. 2022 Apr;63(4):813-820. doi: 10.1080/10428194.2021.2002322. Epub 2021 Nov 15. Leuk Lymphoma. 2022. PMID: 34781825

10

Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission.

Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, Ratanatharathorn V, Modi D, Uberti JP, Deol A. Albanyan O, et al. Among authors: kin a. Hematol Oncol Stem Cell Ther. 2023 Jan 17;16(2):154-157. doi: 10.1016/j.hemonc.2021.07.005. Hematol Oncol Stem Cell Ther. 2023. PMID: 34425096

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

28 results

Search Page